{"id":59718,"date":"2026-03-17T14:12:18","date_gmt":"2026-03-17T06:12:18","guid":{"rendered":"https:\/\/flcube.com\/?p=59718"},"modified":"2026-03-17T14:12:18","modified_gmt":"2026-03-17T06:12:18","slug":"pegbio-inks-rmb10-billion-paidakang-commercialization-deal-with-tenry-pharma-exclusive-china-partnership-for-weekly-glp-1-diabetes-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59718","title":{"rendered":"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug"},"content":{"rendered":"\n<p><strong>PegBio Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2565:HKG\">HKG: 2565<\/a>) has entered into a <strong>strategic cooperation agreement<\/strong> with <strong>Shanghai Tenry Pharmaceutical Co., Ltd.<\/strong> (&#8220;Tenry Pharma&#8221;) for the <strong>exclusive commercialization<\/strong> of <strong>Paidakang (PB\u2011119)<\/strong> in Mainland China, targeting cumulative sales exceeding <strong>RMB10 billion<\/strong> (\u2248\u202fUS$1.4 billion) in a landmark partnership for the weekly GLP\u20111 receptor agonist market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Deal Type<\/strong><\/td><td>Exclusive commercialization partnership<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Paidakang (PB\u2011119) \u2013 weekly GLP\u20111 receptor agonist<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>PegBio Co., Ltd. (HKG: 2565)<\/td><\/tr><tr><td><strong>Commercialization Partner<\/strong><\/td><td>Shanghai Tenry Pharmaceutical Co., Ltd. (private)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China<\/td><\/tr><tr><td><strong>Core Target<\/strong><\/td><td>Cumulative sales &gt; RMB10 billion<\/td><\/tr><tr><td><strong>Upfront\/Total Royalty<\/strong><\/td><td>Approximately HKD 140 million (\u2248\u202fUS$18 million)<\/td><\/tr><tr><td><strong>Revenue Recognition<\/strong><\/td><td>PegBio retains sales revenue recognition<\/td><\/tr><tr><td><strong>IP &amp; Overseas Rights<\/strong><\/td><td>Retained by PegBio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-regulatory-status\">Drug Profile &amp; Regulatory Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>PB\u2011119 (Paidakang)<\/strong> \u2013 new\u2011generation long\u2011acting <strong>GLP\u20111 receptor agonist<\/strong><\/li>\n\n\n\n<li><strong>Administration:<\/strong> <strong>Once\u2011weekly<\/strong> subcutaneous injection (improved adherence vs. daily alternatives)<\/li>\n\n\n\n<li><strong>Indication:<\/strong> <strong>Type 2 diabetes mellitus<\/strong><\/li>\n\n\n\n<li><strong>Approval Status:<\/strong> <strong>NMPA approved<\/strong> (November 2025) \u2013 ready for immediate commercial launch<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Weekly dosing regimen addresses adherence challenges in chronic diabetes management; positioned against daily GLP\u20111 injections and oral DPP\u20114 inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-partnership-structure\">Strategic Rationale &amp; Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>PegBio Position<\/th><th>Tenry Pharma Role<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D &amp; Manufacturing<\/strong><\/td><td>Retains full control; continues pipeline expansion<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Commercialization<\/strong><\/td><td>Revenue recognition; strategic oversight<\/td><td><strong>Exclusive<\/strong> promotion and market deployment in Mainland China<\/td><\/tr><tr><td><strong>Market Access<\/strong><\/td><td>Leverages Tenry\u2019s established hospital and retail pharmacy networks<\/td><td>Deploys existing sales infrastructure and payer relationships<\/td><\/tr><tr><td><strong>Financial Structure<\/strong><\/td><td>HKD 140 million royalty income; RMB10 billion sales target drives upside<\/td><td>Invests in commercialization resources to capture GLP\u20111 market growth<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China GLP\u20111 Landscape:<\/strong> The type 2 diabetes market in China exceeds <strong>RMB60 billion<\/strong> annually, with GLP\u20111 receptor agonists representing the fastest\u2011growing segment (CAGR >20%) driven by superior glycemic control and weight\u2011loss benefits.<\/li>\n\n\n\n<li><strong>RMB10 Billion Target Analysis:<\/strong> Assuming average annual therapy cost of RMB5,000\u20118,000 per patient, the cumulative target implies <strong>1.25\u20112 million patient\u2011years<\/strong> over the partnership term \u2013 achievable given China&#8217;s ~120 million diabetic population and low current GLP\u20111 penetration (&lt;5% of treated patients).<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Paidakang enters a crowded field including Novo Nordisk&#8217;s Ozempic (semaglutide) and Eli Lilly&#8217;s Trulicity (dulaglutide), but its <strong>weekly dosing<\/strong> and <strong>local manufacturing<\/strong> advantages may support pricing flexibility and formulary access.<\/li>\n\n\n\n<li><strong>Tenry Pharma Synergies:<\/strong> Tenry brings established commercial infrastructure in metabolic disease management, potentially accelerating hospital listing and National Reimbursement Drug List (NRDL) negotiations \u2013 critical for volume scaling in China&#8217;s price\u2011sensitive market.<\/li>\n\n\n\n<li><strong>PegBio Strategic Flexibility:<\/strong> Retaining IP and overseas rights preserves optionality for ex\u2011China licensing transactions; the HKD 140 million royalty provides non\u2011dilutive capital to fund pipeline assets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercialization targets, revenue projections, and market penetration expectations for Paidakang. Actual results may differ materially due to risks including competitive dynamics, pricing pressures, reimbursement negotiations, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031601429_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026031601429_c.\"><\/object><a id=\"wp-block-file--media-6f5e17aa-a74c-4484-875a-d0a7ed47402c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031601429_c.pdf\">2026031601429_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026031601429_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6f5e17aa-a74c-4484-875a-d0a7ed47402c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,4078,4361,2105,4643],"class_list":["post-59718","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-diabetes","tag-hkg-2565","tag-hot-targets","tag-pegbio","tag-tenry-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry Pharmaceutical Co., Ltd. (&quot;Tenry Pharma&quot;) for the exclusive commercialization of Paidakang (PB\u2011119) in Mainland China, targeting cumulative sales exceeding RMB10 billion (\u2248\u202fUS$1.4 billion) in a landmark partnership for the weekly GLP\u20111 receptor agonist market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59718\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug\" \/>\n<meta property=\"og:description\" content=\"PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry Pharmaceutical Co., Ltd. (&quot;Tenry Pharma&quot;) for the exclusive commercialization of Paidakang (PB\u2011119) in Mainland China, targeting cumulative sales exceeding RMB10 billion (\u2248\u202fUS$1.4 billion) in a landmark partnership for the weekly GLP\u20111 receptor agonist market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59718\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-17T06:12:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59718#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59718\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug\",\"datePublished\":\"2026-03-17T06:12:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59718\"},\"wordCount\":477,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"HKG: 2565\",\"Hot targets\",\"PegBio\",\"Tenry Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59718#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59718\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59718\",\"name\":\"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-17T06:12:18+00:00\",\"description\":\"PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry Pharmaceutical Co., Ltd. (\\\"Tenry Pharma\\\") for the exclusive commercialization of Paidakang (PB\u2011119) in Mainland China, targeting cumulative sales exceeding RMB10 billion (\u2248\u202fUS$1.4 billion) in a landmark partnership for the weekly GLP\u20111 receptor agonist market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59718#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59718\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59718#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry","description":"PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry Pharmaceutical Co., Ltd. (\"Tenry Pharma\") for the exclusive commercialization of Paidakang (PB\u2011119) in Mainland China, targeting cumulative sales exceeding RMB10 billion (\u2248\u202fUS$1.4 billion) in a landmark partnership for the weekly GLP\u20111 receptor agonist market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59718","og_locale":"en_US","og_type":"article","og_title":"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug","og_description":"PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry Pharmaceutical Co., Ltd. (\"Tenry Pharma\") for the exclusive commercialization of Paidakang (PB\u2011119) in Mainland China, targeting cumulative sales exceeding RMB10 billion (\u2248\u202fUS$1.4 billion) in a landmark partnership for the weekly GLP\u20111 receptor agonist market.","og_url":"https:\/\/flcube.com\/?p=59718","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-17T06:12:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59718#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59718"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug","datePublished":"2026-03-17T06:12:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59718"},"wordCount":477,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","HKG: 2565","Hot targets","PegBio","Tenry Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59718#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59718","url":"https:\/\/flcube.com\/?p=59718","name":"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-17T06:12:18+00:00","description":"PegBio Co., Ltd. (HKG: 2565) has entered into a strategic cooperation agreement with Shanghai Tenry Pharmaceutical Co., Ltd. (\"Tenry Pharma\") for the exclusive commercialization of Paidakang (PB\u2011119) in Mainland China, targeting cumulative sales exceeding RMB10 billion (\u2248\u202fUS$1.4 billion) in a landmark partnership for the weekly GLP\u20111 receptor agonist market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59718#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59718"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59718#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"PegBio Inks RMB10 Billion Paidakang Commercialization Deal with Tenry Pharma \u2013 Exclusive China Partnership for Weekly GLP\u20111 Diabetes Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59718"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59718\/revisions"}],"predecessor-version":[{"id":59720,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59718\/revisions\/59720"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}